Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

(2009) Isabelle Thuret et al.   AIDS

Management of paediatric HIV-1 resistance

(2009) Ravindra K Gupta et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

(2009) L. Wittkop et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

The Spanish HIV BioBank: a model of cooperative HIV research

(2009) Isabel Garcia-Merino et al.   Retrovirology